Chelsea Therapeutics, Inc. Presents Efficacy And Safety Data For NORTHERA At International Congress Of Parkinson's Disease And Movement Disorders

Published: Jun 12, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHARLOTTE, N.C. and STOCKHOLM, Sweden, June 12, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the presentation of an integrated analysis of data from two pivotal multicenter, placebo-controlled, randomized clinical trials showing that NORTHERAâ„¢ (droxidopa) had demonstrated an acceptable safety profile and demonstrated a statistically significant difference in efficacy compared to placebo for improving the symptoms of neurogenic orthostatic hypotension (NOH) in a population comprised chiefly of patients with Parkinson's Disease (PD). The results were presented at the 18th International Congress of Parkinson's Disease and Movement Disorders (MDS) in Stockholm, Sweden, June 8-12, 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news